A Keimyung University research team has reproduced the taste and fragrance of civet coffee, known as “kopi luwak,” by scientifically identifying the digestion and fermentation conditions where civets live.
Consequently, civet coffee could now be mass-produced in a sanitary environment without having to harm animals.
The new civet coffee is available in three varieties, including one with a savory scent and moderate flavor, one with a distinct and fresh flavor, and one with a lot of fruit aroma. More than 40% less caffeine is present than in ordinary civet coffee.
The research team completed a patent application, trademark application, and vegan certification for the research findings, which will be published in academic journals in and outside South Korea.


Tabletop particle accelerator could transform medicine and materials science
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Columbia Student Mahmoud Khalil Fights Arrest as Deportation Case Moves to New Jersey
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
The American mass exodus to Canada amid Trump 2.0 has yet to materialize
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 



